Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Vifor Pharma
Vifor Pharma
Activities:
Manufacturing
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Vifor Pharma to propose Åsa Riisberg for board of directors
Riisberg holds a MSc in Financial Economics and Business Administration from Stockholm School of Economics
Ingredients
Vifor Pharma enters Chinese joint venture with Fresenius Kabi
Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Finance
Vifor Pharma enters commercial diabetes collaboration in the US
The Swiss pharma company will work with US-based Janssen to jointly commercialise INVOKANA (canagliflozin) in the US to address complications of type 2 diabetes
Drug Delivery
PIVOTAL trial confirms long-term safety and efficacy of IV iron dosing
The long-term safety and efficacy of intravenous iron dosing has been confirmed allowing higher Ferritin concentration and transferrin saturation in patients undergoing haemodialysis
Recruitment
Vifor pharma announces management changes
Media
Vifor Pharma proposes Jacques Theurillat as board member
Pharmaceutical
Kissei to market Avacopan in Japan for Vifor Pharma
Vifor Fresenius Medical Care Renal Pharma has granted Japanese pharmaceutical company, Kissei, exclusive rights to develop and commercialise Avacopan in Japan
Subscribe now